Chicago’s AbbVie (NYSE: ABBV) has submitted to the US regulator for approval to market Rinvoq (upadacitinib) for people with active ankylosing spondylitis (AS).
The firm already has a submission underway with the European Medicines Agency (EMA), for people with AS who have responded inadequately to conventional therapy.
In August 2019, Rinvoq received US Food and Drug Administration approval for adults with moderately to severely active rheumatoid arthritis, and the firm submitted in the USA and Europe for approval in active psoriatic arthritis in June 2020.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze